TMS therapy for ADHD is not FDA-cleared. Some clinics use it off-label for adults, and the research so far is promising but mixed: several recent meta-analyses of sham-controlled trials report gains in inattention, especially when the right prefrontal cortex is stimulated, while the largest recent review still rates the evidence for ADHD as inconclusive. Anyone in Boca Raton considering it should treat it as an option to discuss with a psychiatrist after standard treatments, not as a proven first-line therapy.
Insurance usually does not cover TMS when ADHD is the only diagnosis, because the FDA-cleared indications are depression, OCD, smoking cessation and certain migraine pain. When depression or anxiety travels with ADHD, which is common, the picture changes. This guide explains the evidence, who may be a candidate, what a course looks like and what coverage to expect.
Is TMS Therapy FDA-Approved for ADHD?
No. The FDA has cleared TMS devices for several other conditions, but not for ADHD. According to the FDA, TMS was first permitted for major depression in 2008, for pain associated with certain migraine headaches in 2013, and (with the Brainsway Deep TMS system) for obsessive-compulsive disorder on 17 August 2018. TMS is also cleared for smoking cessation. Using it for ADHD is therefore "off-label": a clinician's judgment based on published research. Details are on the FDA announcement about TMS for OCD.
"Off-label" does not mean fringe or proven useless. It means the specific regulatory pathway for ADHD has not been completed while research continues. Patients should ask any provider for a candid, up-to-date account of where the science stands, and should expect the answer to include the words "limited" and "mixed".
Does TMS Therapy for ADHD Work? What the Research Shows
Scientific interest in TMS as an ADHD treatment grew from two lines of evidence. First, neuroimaging studies have documented reduced activation and altered connectivity in the dorsolateral prefrontal cortex (DLPFC), the frontal region that governs executive function, working memory and attentional control. Second, TMS was already shown to modulate DLPFC activity in depression, which made ADHD a logical next area of investigation. A 2025 meta-analysis in Frontiers in Psychiatry also pooled 17 studies and found reduced short-interval intracortical inhibition, a TMS-measured marker of cortical inhibition, in people with ADHD compared with healthy controls.
The treatment trials are small, and the pooled results differ by review. Here is what the most recent meta-analyses reported:
- 2024, Brazilian Journal of Psychiatry (six sham-controlled trials, 169 participants). No overall difference between rTMS and sham for ADHD symptoms (SMD -0.24, p = 0.17). But targeting the right prefrontal cortex did beat sham (SMD -0.49, p = 0.03), while the left prefrontal cortex did not. Inattention improved; hyperactivity, impulsivity and depression scores did not. Dropout was not significantly higher with rTMS. See the PubMed record.
- 2023, BMC Psychiatry (five randomized trials, 189 participants). rTMS improved sustained attention (SMD 0.54) and processing speed (SMD 0.59) on standardized tasks, but not memory or executive function.
- 2025, Frontiers in Psychiatry (eight samples from seven randomized trials). rTMS improved ADHD symptoms compared with control conditions, with a pooled SMD of 0.45 (95% CI 0.19 to 0.70).
- Journal of the American Academy of Child and Adolescent Psychiatry (recent review; 33 randomized trials of brain stimulation, 1,049 participants with ADHD, including 7 rTMS trials). The authors concluded that evidence for therapeutic efficacy "remains inconclusive", although the rTMS trials showed benefit for inattention and for hyperactivity/impulsivity, and tolerability was favorable. No dose-response relationship was found for rTMS. See the PubMed record.
A 2022 umbrella review of brain-stimulation treatments in mental disorders reached a similar position. For ADHD, the only intervention it listed as effective against sham was transcranial direct current stimulation (tDCS, a different technique with a small effect, SMD 0.23, moderate certainty); TMS for ADHD was not on that list. Other conditions, such as depression (TMS, SMD 0.51, moderate certainty), fared better.
Taken together, the fair summary is this. The direction of findings is encouraging, particularly for inattention and right-sided targets, but trials are few, small and short, protocols differ, and the strongest recent review calls the evidence inconclusive. TMS for ADHD is far less established than TMS for major depression, which has been studied in large multi-site trials for more than two decades.
Right DLPFC stimulation has received the most attention for ADHD. The right prefrontal cortex plays a central role in inhibitory control and sustained attention, two core deficits in the inattentive and combined presentations. High-frequency rTMS applied there is thought to enhance local excitability and improve signal transmission through frontostriatal pathways that regulate dopamine and norepinephrine activity. This differs from the left DLPFC target most commonly used for depression, which is one reason an individual evaluation matters before any protocol is designed.
Researchers have also explored cerebellar TMS as a complementary approach. The cerebellum, long considered a purely motor structure, is now understood to participate in cognitive timing, attentional processes and the regulation of prefrontal circuits. Early studies suggest it may work alongside DLPFC-targeted approaches for some presentations, but this work is at an earlier stage and is not standard clinical practice.
ADHD in Adults: Why Standard Treatment Sometimes Falls Short
ADHD is a neurodevelopmental condition defined by persistent difficulties with attention, impulse control and, in some presentations, hyperactivity. The National Institute of Mental Health says symptoms begin in childhood and usually continue into the teen years and adulthood, and researchers estimate that more than half of children diagnosed with ADHD carry clinically significant symptoms into adulthood. NIMH statistics from a national survey of US adults aged 18 to 44 (2001-2003) put current adult ADHD at 4.4% (5.4% of men, 3.2% of women) and lifetime prevalence at 8.1%. The CDC notes that many adults are diagnosed for the first time in adulthood.
In adults, the hyperactive component often quiets down while attentional challenges dominate: trouble sustaining focus, frequent task-switching, losing track of deadlines, forgetting conversations mid-sentence and starting a dozen projects without finishing one. The CDC adds that a diagnosis typically involves a symptom checklist and behavioral history, and that the provider will determine whether symptoms were present before age 12 and may need to rule out conditions that mimic or accompany ADHD, such as anxiety, depression, sleep problems and substance misuse. Executive dysfunction sits at the core: the capacity to plan, organize, initiate tasks and regulate emotional responses depends heavily on the prefrontal cortex, and in ADHD that circuitry is dysregulated in ways willpower or time-management strategies cannot simply override.
Adults with ADHD are also more likely than the general population to experience major depression, generalized anxiety, substance use disorders and sleep disturbances. These conditions share underlying neurobiological mechanisms and tend to worsen one another. A person in Boca Raton who has been told their recurring depression is hard to treat may, on closer evaluation, be living with both depression and undiagnosed ADHD, a combination that standard antidepressant protocols rarely address fully.
First-line ADHD treatment remains medication, most commonly stimulants such as amphetamine salts or methylphenidate, combined with behavioral or cognitive therapy. For many people these work well. But a meaningful subset of patients cannot tolerate stimulants because of cardiovascular concerns, co-occurring anxiety that worsens on stimulants, a personal or family history of substance misuse, or side effects such as appetite suppression, sleep disruption or emotional blunting. Non-stimulant alternatives including atomoxetine, viloxazine, guanfacine and clonidine can help, but often produce more modest results and have their own tolerability challenges. NIMH lists neuromodulation among newer approaches under study alongside neurofeedback, cognitive training and mindfulness. It is in this gap, where medication is insufficient or not an option, that TMS for ADHD is usually discussed.
How TMS Works: A Brief Primer
Transcranial magnetic stimulation delivers precisely targeted magnetic pulses through the scalp and skull to modulate neuronal activity in specific cortical regions. A coil is held against the head; the magnetic field passes through tissue without electrical current entering the body, which is why TMS is non-invasive and requires no anesthesia, no sedation and no recovery period. The patient sits in a chair, remains fully awake and typically drives home after each session. For the full overview, see the complete guide to TMS.
The frequency and pattern of pulses determine the effect. High-frequency repetitive TMS (rTMS) tends to increase cortical excitability in the targeted area. Theta-burst stimulation (TBS), a compressed, more modern protocol, can achieve similar effects in a fraction of the time, often just three to five minutes of actual stimulation. Low-frequency protocols work in the opposite direction, quieting overactive regions. This flexibility is what makes TMS useful across several psychiatric and neurological conditions, each involving different circuit-level patterns.
Which Brain Regions Are Targeted for ADHD, and Why It Matters
The dorsolateral prefrontal cortex sits in the lateral frontal lobe and functions as the brain's executive coordinator. It sustains attention, filters distractions, holds information in working memory long enough to act on it, and exerts top-down control over the amygdala and other subcortical structures involved in emotional reactivity and impulsivity. In ADHD this region consistently shows reduced gray matter volume, lower resting-state activity and weaker connectivity to the striatum, the reward and motivation hub whose dysregulation helps explain why people with ADHD struggle to sustain effort on unstimulating tasks despite being capable of intense focus on engaging ones.
When TMS applies excitatory pulses to the right DLPFC in someone with ADHD, the goal is to increase activation in underactive circuitry. Over a full course, repeated stimulation is thought to promote lasting changes in synaptic strength through mechanisms similar to long-term potentiation, the cellular process underlying learning and memory. This is why TMS effects, whether for depression or ADHD, tend to be cumulative rather than immediate.
Patients with ADHD show somewhat different patterns of frontal hypoactivation, so a careful assessment considers whether right DLPFC, left DLPFC, bilateral or an alternative target is the most appropriate starting point, and how co-occurring depression or anxiety should shape the protocol. The 2024 meta-analysis above is a reminder of why: left-sided stimulation showed no benefit on its own.
TMS for ADHD in Adults: Who May Be a Candidate?
Not every adult with ADHD is an equally strong candidate for TMS, and a responsible evaluation helps determine who is most likely to benefit. These are the profiles that come up most often in clinical discussion; none guarantees a result, given the evidence above.
- People who cannot tolerate stimulant medications. Cardiovascular conditions such as hypertension, arrhythmia or heart disease can make stimulants inadvisable. Anxiety disorders worsened by stimulants are common in the ADHD population. A history of substance use disorder, which overlaps significantly with ADHD, may make patients and providers reluctant to rely on Schedule II controlled substances. TMS offers a non-pharmacological pathway that avoids these particular concerns.
- People with ADHD and comorbid depression or anxiety. This is clinically one of the most compelling profiles. TMS protocols can be designed with both conditions in mind, and the depression component may qualify for insurance coverage, which makes treatment far more financially accessible than an ADHD-only approach. See the guides to TMS for anxiety and depression and treatment-resistant depression.
- People who responded only partially to medication. Some patients find stimulants help to a point but leave executive function deficits, emotional dysregulation or attentional inconsistency in place. TMS targets circuit-level activity that medication does not fully reach for every individual.
- Adults seeking a non-pharmacological maintenance strategy. After a successful course, some patients move to periodic maintenance sessions with reduced reliance on daily medication, for instance because of professional drug-screening requirements, personal preference or concerns about long-term cardiovascular effects. See how long TMS therapy lasts for how maintenance typically works.
- People in recovery from substance use disorder. ADHD and addiction are closely linked: impulsivity, reward-pathway dysregulation and self-medication are well documented in the overlap. For patients in recovery who cannot safely take Schedule II stimulants, TMS carries no known misuse potential and adds no new drug to a fragile recovery. Background is in the pages on dual diagnosis and addiction treatment and where TMS fits.
Standard TMS exclusions apply whatever the indication. Metallic implants in or near the head, including certain cochlear implants, specific aneurysm clips or deep brain stimulators, preclude TMS in most cases. A personal history of seizures or epilepsy, active cranial lesions or certain other neurological conditions requires careful review. A complete medical intake should screen for all of these before any plan is discussed. For safety and tolerability, see TMS side effects and safety.
Adolescents are a separate question, because the research populations, protocols and consent issues differ. See TMS therapy for teens and adolescents.
How TMS for ADHD Differs from TMS for Depression
The core technology and non-invasive mechanism are identical, but the protocol details can differ in meaningful ways.
For major depressive disorder, the most established, FDA-cleared approach targets the left DLPFC with high-frequency rTMS over a course of typically 36 sessions, five days per week, refined through decades of large trials. For ADHD, providers most commonly target the right DLPFC, or use bilateral stimulation when the clinical picture warrants it, with protocols adapted from published research rather than a single standardized pathway. Session frequency, intensity and total session count may all vary depending on whether ADHD is the sole focus or is being addressed alongside a mood or anxiety disorder.
Theta-burst stimulation has also been studied in ADHD populations with promising preliminary results. TBS can deliver stimulation in three to five minutes per session rather than the 20 to 40 minutes of standard rTMS, an advantage for people with demanding schedules or for whom sitting still is difficult. Protocols continue to evolve, so it is reasonable to ask a prospective provider which approach they would recommend and what published research supports it for your presentation.
What to Expect During ADHD-Focused TMS
The process begins well before the first pulse. The initial evaluation covers your psychiatric and medical history, prior treatments and responses, current medications and the symptom domains causing the most impairment. This is a substantive clinical conversation aimed at deciding whether TMS is appropriate, what protocol is logical and what expectations are realistic.
If TMS is recommended, a mapping session establishes your motor threshold: the minimum stimulation intensity that produces a detectable motor response in your hand. This calibration sets pulse intensity for your physiology, accounting for individual variation in skull thickness and cortical excitability.
Treatment sessions then typically run five days per week. You sit in a reclined chair in a quiet clinical room while a trained technician positions the coil over the target site. You feel a rhythmic tapping on the scalp and hear a clicking sound from the device, which is unusual at first but well tolerated by most patients after the first few sessions. You remain awake throughout, sessions run roughly 20 to 40 minutes depending on the protocol, and you can drive yourself home and return to work or family responsibilities straight away.
Throughout the course, your clinician should track progress with validated rating scales: standardized ADHD scales, plus depression and anxiety measures where relevant. Protocol adjustments are then based on objective data rather than impressions.
Most standard courses run four to six weeks. Some patients report changes in mental clarity, task initiation and attentional stamina in the second or third week. For others the clearest gains appear in the weeks after the course ends, as the brain consolidates the changes. Because ADHD trials are short and small, nobody can yet promise a typical timeline or how long benefit lasts.
ADHD Rarely Travels Alone: Treating the Full Picture
One of the strongest practical arguments for a TMS evaluation when ADHD is your main concern is that co-occurring conditions can be addressed within the same framework. In clinical populations, ADHD co-occurs with major depression in a large share of adult patients, with some estimates placing the overlap between a third and a half of adults presenting for ADHD care. Anxiety disorders overlap even more often, and substance use disorder, PTSD and chronic sleep disturbance occur at elevated rates. Exact figures vary by study population and diagnostic method, but the pattern is robust.
Each pairing creates a challenge that single-condition treatment rarely solves. Treating attention without touching underlying depression limits functional gains, because low motivation, anhedonia and cognitive slowing keep eroding performance. Antidepressant therapy that ignores ADHD may lift mood partially while leaving executive dysfunction, impulsivity and the relationship difficulties that follow untouched. A thorough evaluation accounts for every condition present, and for someone with ADHD and depression, a TMS protocol can address both the attentional and mood-related components of prefrontal dysregulation, with the depression component potentially qualifying for coverage. When ADHD is part of a complex picture, a provider with real TMS experience, rather than a general outpatient setting, is better placed to weigh these decisions.
Insurance Coverage and Cost for ADHD-Related TMS in Boca Raton
Insurance is among the first practical questions most patients raise. Because TMS is not FDA-cleared specifically for ADHD, major carriers, including Medicare, most Medicaid plans and the majority of commercial insurers in Florida, generally do not cover it when the primary documented diagnosis is ADHD alone. Enter the evaluation with that expectation.
The picture changes when a comorbid condition is present. If you carry a documented diagnosis of major depressive disorder alongside ADHD and a treatment history showing an adequate but insufficient response to antidepressant medications, the depression component may qualify under the standard TMS criteria carriers have applied since the FDA's initial clearance for depression in 2008. A course addressing both mood and attention can then be structured in a single treatment period, with the benefit applying to the covered indication. This is a legitimate pathway provided the documentation accurately reflects the diagnosis and treatment history.
For patients without a qualifying comorbid diagnosis, treatment would be self-pay. Out-of-pocket costs for a full course vary by provider, protocol and market and change over time, so ask a provider for current, specific pricing in writing rather than rely on a number that may have shifted. Financing arrangements may be available. For how coverage criteria and pricing work in general, see the guide to TMS cost and insurance coverage.
Before any financial commitment, ask for a benefits verification: the provider reviews your plan documents and treatment history and explains what is and is not covered. Ask whether the clinic handles this step and whether you can get the answer in writing, so there are no surprises.
Finding TMS Therapy for ADHD in Boca Raton, Miami and Hollywood
Because ADHD is an off-label use, TMS for ADHD is offered by only some TMS practices, and many clinics in Boca Raton, Miami-Dade and Broward (where Hollywood is located) describe their programs mainly around depression. Searching for a nearby clinic is therefore less useful than asking the right questions of whichever clinic you consider.
Questions worth putting to any provider:
- Who diagnoses and monitors the ADHD, and is a psychiatrist involved in the treatment plan?
- Which brain target and protocol would be used, and what published research supports it for ADHD?
- Is ADHD treated as the main indication, or is the plan built around a covered diagnosis such as depression?
- What would be billed to insurance, what would be self-pay, and can that be confirmed in writing?
- How is progress measured, and what happens if there is no improvement after the course?
For a fuller checklist, see how to choose a TMS provider in Boca Raton.
Frequently Asked Questions
Is TMS therapy for ADHD effective?
The evidence is encouraging but not conclusive. A 2024 meta-analysis of six sham-controlled trials found no overall benefit but a benefit for inattention when the right prefrontal cortex was targeted, and a recent review in the Journal of the American Academy of Child and Adolescent Psychiatry called the evidence for brain stimulation in ADHD inconclusive. Larger, longer trials are still needed.
Does TMS work for ADHD in adults?
A 2023 meta-analysis of five randomized trials that included adults (mean adult age about 33) found improved sustained attention and processing speed with rTMS but not memory or executive function. Results are not guaranteed for any individual, and a clinician should review your history before recommending a course.
Is TMS for ADHD covered by insurance in Florida?
Because TMS is not FDA-cleared for ADHD, most Florida plans do not cover it for that diagnosis alone. If you have a documented comorbid condition such as major depressive disorder that meets the criteria insurers apply to TMS, the course may be covered under that indication. Ask the provider to complete a benefits verification before treatment begins.
How many TMS sessions are needed for ADHD?
There is no single standardized ADHD course. The JAACAP review found no significant dose-response relationship for rTMS in ADHD, and protocols vary by clinic. Courses are often modeled on depression schedules of five sessions per week for four to six weeks, and some patients have maintenance sessions afterward. Your provider should set out the planned number of sessions and review points in advance.
Can I continue taking my ADHD medication during TMS treatment?
In most cases, yes. TMS is generally compatible with stimulant and non-stimulant ADHD medications such as atomoxetine or viloxazine and with most other psychiatric medications. Some patients and their prescribers reassess medication after a completed course. Disclose all current medications and supplements at intake so any considerations can be reviewed before you begin.
What does a TMS session feel like?
You sit in a reclined chair while the coil is positioned near the target area of your scalp. You feel a rhythmic tapping and hear a clicking sound. Most patients find it manageable after the first few sessions. There is no sedation, no needles and no recovery time, so you can drive yourself to and from appointments.
How soon might I notice improvements in focus and attention?
Individual responses vary considerably. Some patients describe clearer thinking, task initiation and sustained attention in the second or third week; others notice the largest gains in the weeks after the course ends. Standardized symptom tracking during the course helps you and your clinician interpret what you are experiencing.
Can TMS help if my ADHD is accompanied by depression or anxiety?
It can be part of the plan. When ADHD co-occurs with depression, which is common, a TMS protocol can be designed with both conditions in mind, and the depression component may qualify for insurance coverage. Treating the full diagnostic picture rather than one condition in isolation tends to give more durable gains in daily functioning, though outcomes vary.
Is TMS therapy for ADHD available in Miami and Hollywood?
Some TMS practices in Miami-Dade and Broward County, as well as Palm Beach County, may offer ADHD protocols off-label, but availability varies and many programs focus on depression. Ask each clinic directly whether ADHD is treated, by whom, under which protocol and what is billed to insurance.
If you are living with ADHD and have not found adequate relief through medication, therapy or other approaches, a licensed psychiatrist or other qualified clinician can help you decide whether TMS belongs in your treatment plan. Questions worth bringing to a first appointment include how the provider evaluates ADHD, what evidence supports TMS for it and what coverage to expect.